Cargando…
Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome
5-Azacytidine (5-AZA) was the first drug to be approved for the treatment of high-risk myelodysplastic syndrome (MDS). The adverse event profile of this drug appears favorable compared with the conventional intensive chemotherapy that is used for MDS or acute myeloid leukemia. However, uncommon adve...
Autores principales: | MELCHARDT, THOMAS, WEISS, LUKAS, PLEYER, LISA, STEINKIRCHNER, SUSANNE, AUBERGER, JUTTA, HOPFINGER, GEORG, GREIL, RICHARD, EGLE, ALEXANDER |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834563/ https://www.ncbi.nlm.nih.gov/pubmed/24260071 http://dx.doi.org/10.3892/ol.2013.1629 |
Ejemplares similares
-
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial
por: Weiss, Lukas, et al.
Publicado: (2017) -
Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006) -
Cytomegalovirus reactivation and its clinical impact in patients with solid tumors
por: Schlick, Konstantin, et al.
Publicado: (2015) -
A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine
por: HISASUE, Masaharu, et al.
Publicado: (2021) -
Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)